Pelosi Discloses Major Intel and Uber Call Option Purchases Worth Up to $6 Million 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
Samsung and SK Hynix Shares Jump After Micron Earnings Boost AI Chip Optimism 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
New York, Feb. 22, 2016 -- Intrommune Therapeutics, a specialty biopharmaceutical company developing a patient-friendly platform for the treatment of food allergies, today announced that company CEO, Michael Nelson, will present at the New York Venture Capital Association 2016 Health & Bio Technology Summit on Tuesday, February 23rd at 4pm at the Microsoft Technology Center in New York, NY.
Intrommune’s lead product, INT-301, is being developed for the treatment of peanut allergies. Peanut allergy is a potentially deadly disease which affects 1.5 million children at an estimated cost of $6.25 billion per year to families in the United States. There is currently no treatment for this condition.
In addition to INT-301 for peanut allergy, Intrommune is also developing the OMIT platform to treat other common food allergies. The 8 most common allergies account for 90% of food allergies in the US. 15 million Americans, including 6 million children, have one or more food allergies.
About Oral Mucosal Immunotherapy
Food allergies affect an estimated 15 million Americans, including 6 million children, and over 220 million people worldwide. Allergen-specific immunotherapy is the only treatment modality that targets the root cause of the disease, consistently exposing the allergy sufferer’s immune system to small amounts of allergen proteins to desensitize them to the allergens over time. There is currently no commercially-available allergy immunotherapy product for food allergies. Oral mucosal immunotherapy (OMIT) uses a specially formulated toothpaste to stabilize and deliver allergenic extracts to the areas of the oral cavity with the greatest potential for allergy desensitization. OMIT promises advantages over existing approaches to allergy immunotherapy due to its targeted delivery, simplified administration, and ease of long-term patient adherence.
About Intrommune Therapeutics
Intrommune is developing the revolutionary oral mucosal immunotherapy (OMIT) treatment platform for food allergies. Intrommune’s lead product, INT-301, is expected to be a safe, effective and convenient therapy for patients who suffer from peanut allergy. OMIT is designed to deliver proteins, such as immunotherapeutic agents, to the immune system while the user brushes their teeth. OMIT is a long-term, patient-friendly, disease-modifying solution for the 220 million people, including 9 million adults and 6 million children in the U.S., who suffer from this life-altering condition.
Danya Glabau Director of Medical Affairs Intrommune Therapeutics [email protected]
